EGFR and metastatic colorectal cancer: Targeted therapy of metastatic colorectal cancer (mCRC) using monoclonal antibody (moAb) anti-epidermal growth factor receptors (EGFR) agents, such as cetuximab (CTX) or panitumumab, is the treatment strategy of choice in patients characterised by a wild type (wt) KRAS gene status (1–3).